Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature

Background null In the last few years, several new drugs such targeted therapy and immunotherapy have shown activity and have been approved for the treatment of metastatic renal cell carcinoma (mRCC). In mRCC, nivolumab, anti-PD-1 antibody, has recently been approved for the treatment after failure of anti-angiogenic treatment. Literature data are very limited in some subgroups of patients such as those with end-stage renal disease requiring...